All In Biotech

Drug Trial Radar · NCT03120364

Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

A Randomized, Double Blinded, Multi-center Phase III Confirmatory Study to Assess the Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

Last checked: Nov 19, 2026Latest source record: Apr 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 824 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

824

Actual

Start

Sep 9, 2015

Primary completion

Dec 16, 2015

Study completion Apr 28, 2016

Sponsor

Lead sponsor
SK Chemicals Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study assesses non-inferiority by comparing GMR(Geometric Mean Ratio) of NBP608 to Zostavax which are evaluated by gpELISA (Glycoprotein Enzyme Linked Immunosorbent Assay). Total of 824 healthy subjects (412 subjects per treatment arm) aged 50 and over are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned.

Conditions

  • Herpes Zoster

Interventions

  • NBP608Biological

    Preparation of Oka/SK strain of live, attenuated zoster virus

  • ZostavaxBiological

    Preparation of Oka/Merck strain of live, attenuated zoster virus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GMR(Geometric Mean Ratio) of VZV(Varicella-Zoster Virus) antibody titer measured by gpELISA(Glycoprotein Enzyme-Linked Immnosorbent Assay)Time frame: 6 weeks after IP(Investigational Product) vaccination
  2. GMR(Geometric Mean Ratio) ratio of NBP608 to Zostavax measured by gpELISATime frame: 6 weeks after IP(Investigational Product) vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Guro Hospital

    Seoul, Guro-gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.